Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 7, 2016
Event: Regulation FD Disclosure regarding a press release announcing the submission of a New Drug Application (NDA) for Yuvvexy (TX-004HR).
Key Financial Metrics
This filing is a current report regarding a regulatory milestone and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Yuvvexy (TX-004HR). No financial changes versus prior periods are disclosed in this document.
Outlook, Risks, and Management Commentary
Management Commentary: The company announced the NDA submission for Yuvvexy, a product intended for the treatment of vaginal atrophy.
Risks and Contingencies: The filing does not explicitly detail risks or contingencies beyond the standard regulatory process implied by an NDA submission. The outcome of the FDA review remains a contingency for future commercialization.
Key Facts for Investor Verification
- Verify the status of the NDA for Yuvvexy (TX-004HR) with the FDA.
- Review the full text of the press release (Exhibit 99.1) for specific indications and trial data supporting the submission.
- Monitor future filings for FDA acceptance of the NDA and any subsequent review timelines.
- Check subsequent 10-Q or 10-K filings for the financial impact of this development on the company's cash burn and runway.